Drug for treating pulmonary hypertension

The compound 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one addresses the hypotensive side effects of existing sGC treatments by maintaining therapeutic efficacy in pulmonary hypertension without affecting systemic blood pressure, providing a safer antihypertensive solution for pulmonary hypertension.

WO2024242594A1PCT designated stage expired Publication Date: 2024-11-28OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU IPHAR
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/RU2024/050109
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current sGC stimulants and activators used to treat pulmonary hypertension have a negative side effect of hypotension on systemic blood pressure, limiting their use despite providing therapeutic benefits in reducing pulmonary artery pressure and right ventricular load.

Method used

The compound 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one is used to treat pulmonary hypertension, which does not cause hypotensive effects on systemic blood pressure at normal levels while maintaining antihypertensive efficacy in elevated pulmonary pressures.

Benefits of technology

This compound effectively reduces pulmonary vascular resistance and pulmonary artery pressure without lowering systemic blood pressure, offering a safer treatment option for pulmonary hypertension by eliminating endothelial dysfunction and normalizing hemodynamic parameters.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure RU2024050109_28112024_PF_FP_ABST
    Figure RU2024050109_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to the field of pharmacology and medicine, and more particularly to drugs for treating pulmonary hypertension. 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one of formula I is used as a drug for treating pulmonary hypertension with no adverse hypotensive effect on systemic arterial pressure. The drug of formula I is used to normalize the haemodynamic parameters of the pulmonary circulation, which includes lowering elevated pressure in the pulmonary artery and the right ventricle, lowering pulmonary vascular resistance and restoring the cardiac output of the right ventricle. The drug of formula I is used in the case of pulmonary arterial hypertension or chronic thromboembolic hypertension. Optimally, the drug of formula I is administered to mammals in doses of from 1.5 to 200 mg.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] A REMEDY FOR THE TREATMENT OF PULMONARY HYPERTENSION

[0002] Field of technology to which the invention relates

[0003] The invention relates to the field of pharmacology and medicine, in particular to agents that can be used to treat pulmonary hypertension.

[0004] Prior art

[0005] Pulmonary hypertension is a group of diseases characterized by a progressive increase in pulmonary vascular resistance and pulmonary artery pressure, which leads to the development of right ventricular failure and premature death.

[0006] The pathogenesis of pulmonary hypertension is based on the narrowing of blood vessels in the lungs, their thrombosis and remodeling (excessive cellular proliferation and fibrosis of the vascular wall), which worsens blood flow, increases pulmonary vascular resistance and pressure in the pulmonary artery. The latter leads to an increase in the load on the right ventricle of the heart and its hypertrophy, but gradually the compensatory mechanisms prove insufficient and right ventricular heart failure occurs [1].

[0007] An important link in the pathogenesis of various pulmonary hypertensions, including pulmonary arterial hypertension (hereinafter referred to as PAH), chronic thromboembolic pulmonary hypertension (hereinafter referred to as CTEPH) and other forms of pulmonary hypertension, is endothelial dysfunction, which is manifested by a decrease in the synthesis of vasodilating factors (nitric oxide (NO), prostacyclin), hyperproduction of vasoconstrictor substances (endothelial-1, thromboxane A2, serotonin), the formation of prothrombotic conditions and the development of inflammatory reactions in the vascular wall, which ultimately leads to hypertension, smooth muscle hypertrophy, thrombosis and vascular remodeling [2].

[0008] The functional state of the vascular endothelium is largely determined by the NO-sGC-cGMP (nitric oxide - soluble guanylate cyclase - cyclic guanosine monophosphate) signaling pathway, which plays an important role in the body, especially in the regulation of the cardiovascular system. The main elements of this signaling pathway are the enzymes endothelial NO synthase (eNOS), responsible for the synthesis of nitric oxide (NO), and soluble guanylate cyclase (sGC), responsible for the synthesis of cyclic guanosine monophosphate (cGMP) [3]. NO is synthesized by eNOS in the endothelial cells of blood vessels and activates sGC, which is present in many cells, including endothelial and smooth muscle cells of blood vessels, platelets, leukocytes, etc. Activation of sGC leads to an increase in the synthesis of cGMP, a messenger molecule that is responsible for the relaxation of smooth muscle cells of the vascular wall (vasodilating or antihypertensive effect).In addition to the vasodilating effect, cGMP also helps reduce inflammation, proliferation and fibrosis. Many cardiovascular diseases, such as arterial hypertension, pulmonary hypertension, heart failure and others are associated with disruption of the NO-sGC-cGMP signaling pathway [4, 5].

[0009] Bayer discovered two different classes of substances that enhance sGC activity independently of NO, which were called sGC stimulators and activators. Both classes of substances directly bind to sGC and allosterically modulate the enzyme's activity [6].

[0010] The sGC stimulator BAY 63-2521 (code name) or riociguat (international nonproprietary name) was the first drug in this class approved for the treatment of patients with PAH and CTEPH. Riociguat is methyl H-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1 H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamate:

[0011] Due to stimulation of sGC, riociguat has a pronounced hypotensive and antihypertensive effect. Thus, in studies on spontaneously hypertensive SHR rats, riociguat, when administered orally once, led to a long-term and dose-dependent decrease in mean arterial pressure [7, Fig. 1]

[0012] It should be noted that SHR rats are a natural model of progressive arterial hypertension, which develops in them due to dysfunction of the vascular endothelium. Therefore, SHR rats are used as a standard model for studying sGC stimulators or activators, which, due to their mechanism of action, are able to restore the properties of the vascular wall under conditions of endothelial dysfunction. Preclinical and clinical studies have shown that riociguat improves hemodynamic parameters in animals with a model of pulmonary hypertension and in patients with pulmonary hypertension - it reduces pulmonary vascular resistance, pressure in the pulmonary artery and the right ventricle of the heart. However, riociguat reduces not only the pressure in the pulmonary artery (i.e. pressure in the pulmonary circulation), but also systemic arterial pressure in the systemic circulation.Thus, in rabbits with a model of pulmonary arterial hypertension, riociguat at doses of 1 and 10 mg / kg dose-dependently reduced both pulmonary artery pressure and systemic arterial pressure by 5-15% [8, Fig. 2].

[0013] Riociguat is recommended for use as an antihypertensive agent for the treatment of a number of forms of pulmonary hypertension, such as pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Based on the results of clinical studies and clinical experience, it has been established that the most common and dangerous side effect of riociguat is hypotension (a decrease in systemic blood pressure), which manifests itself as headaches, dizziness, and peripheral edema [9].

[0014] Another sGC stimulator, vericiguat, was approved in 2021 for the treatment of patients with heart failure. It has much in common with riociguat in its chemical structure - it is methyl -[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate:

[0015] The most common side effect of vericiguat, as well as riociguat, is hypotension, as evidenced by the results of clinical studies of vericiguat in patients with heart failure

[0010] .

[0016] Other sGC stimulants, including praliciguat, are at various stages of development.

[0017] which differ significantly in chemical structure from riociguat, although they have some common structural fragments.

[0018] As follows from [11, Fig. 3], praliciguat in doses from 0.3 to 10 mg / kg reduces arterial pressure not only in spontaneously hypertensive SHR rats (by approximately 27% at the maximum dose), but also in normotensive Wistar rats - by 10-12% from the initial level, which reflects the side hypotensive effect of the drug. sGC activators are also known, which differ in the mechanism of binding to the target from sGC stimulators. Activators bind to oxidized, heme-free sGC, formed under the influence of oxidative stress in many cardiovascular diseases, and act independently of the presence of NO. Examples of sGC activators include cinaciguat

[0019]

[0020] sGC activators exhibit potent vasodilatory activity at nanomolar concentrations. However, clinical development of cinaciguat and ataciguat was discontinued precisely because of the pronounced side hypotensive effect on systemic arterial pressure

[0012] .

[0021] Thus, sGC stimulators and activators have an antihypertensive effect, useful for the treatment of pulmonary hypertension and a number of other cardiovascular diseases. However, all of them have a dangerous side hypotensive effect on systemic blood pressure, which greatly limits the use of such drugs. In connection with the above, the search for new compounds - sGC stimulators or activators for the treatment of pulmonary hypertension and other cardiovascular diseases, capable of eliminating the manifestations of endothelial dysfunction, reducing high pressure in the pulmonary artery and right ventricle of the heart, having an antihypertensive effect at an elevated level of systemic blood pressure, but not having a negative hypotensive effect on systemic blood pressure at its normal level, is of great importance for modern pharmacology. The antithrombotic and antiatherosclerotic agent 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one of formula I is known which is used as an activator of the enzyme soluble guanylate cyclase, an inhibitor of platelet aggregation with antihypertensive activity for the production of a drug for the treatment of cardiovascular diseases

[0013] .

[0022] Disclosure of invention

[0023] The technical problem to be solved is the elimination of the negative side hypotensive effect on systemic blood pressure in the treatment of pulmonary hypertension.

[0024] The technical result is the absence of a negative side hypotensive effect on systemic blood pressure while maintaining a positive therapeutic effect in the treatment of pulmonary hypertension, including the elimination of manifestations of endothelial dysfunction and normalization of hemodynamic parameters of the pulmonary circulation (reduction of increased pressure in the pulmonary artery and right ventricle of the heart, reduction of pulmonary vascular resistance, restoration of cardiac output of the right ventricle).

[0025] The technical result is achieved by the fact that 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene] indolin-3-one of formula I is used as a means for treating pulmonary hypertension without a side hypotensive effect on systemic blood pressure.

[0026] In one embodiment of the invention, it is possible to use 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one of formula I for the treatment of pulmonary arterial hypertension.

[0027] In another embodiment of the invention, it is possible to use 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one of formula I for the treatment of chronic thromboembolic pulmonary hypertension. Preferably, 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one of formula I is used by oral administration of a dose of 1.5 to 200 mg.

[0028] Experiments on laboratory animals and clinical studies have shown that the compound of formula I does not have a hypotensive effect on systemic BP in mammals, including humans, at its initially normal level (see examples 1 and 2). At the same time, the compound of formula I is at least as good as the known agents in terms of the strength and duration of the antihypertensive effect at an initially elevated BP level - in spontaneously hypertensive SHR rats (example 1). The studies have also shown that the compound of formula I does not reduce systemic BP in animals with a pulmonary hypertension model (example 4). At the same time, the compound of formula I is as effective as riociguat - normalization of the hemodynamic parameters of the pulmonary circulation in standard models of various forms of pulmonary hypertension: PAH and CTEPH. Thus, in the PAH model in rats, the compound of formula I, like riociguat, reduces elevated pressure in the right ventricle of the heart (example 4).In the CTEPH model, the compound of formula I, like riociguat, reduces elevated mean pulmonary artery pressure and pulmonary vascular resistance and restores reduced cardiac output (Example 3).

[0029] The key difference of the compound of formula I, revealed in the course of the studies, is that the compound of formula I, unlike riociguat or other known sGC stimulators and activators, does not exert a hypotensive side effect on systemic BP at its initially normal level. Thus, the compound of formula I does not affect systemic BP in normotensive rats or the BP value in healthy people with initially normal BP (examples 1 and 2). Moreover, in the PAH model (example 4), it was found that the compound of formula I even restored (increased to values ​​close to the normal level) the reduced systemic BP in rats with PAH. Riociguat, on the contrary, reduced systemic BP even more, which is a dangerous side effect.

[0030] It has been shown on the PAH model that the antihypertensive effect of the compound of formula I is based on its ability to eliminate manifestations of endothelial dysfunction, in particular, impairment of the vasodilating (vasoconstrictor) properties of the endothelium. At the same time, the compound of formula I is superior to riociguat in its effect on the vasodilating properties of the endothelium, which is manifested in the normalization of the parameters of endothelium-dependent vasodilation (example 4). Thus, the compound of formula I, unlike riociguat or other known sGC stimulators and activators, does not have a dangerous hypotensive effect on systemic BP at its normal or low value. This allows the safe use of drugs based on the compound of formula I as an antihypertensive agent for the treatment of pulmonary hypertension, as well as other cardiovascular diseases.

[0031] Fig. 1, taken from publication [7], shows the effect of riociguat upon its single oral administration at doses from 0.03 to 3 mg / kg on systemic arterial pressure in spontaneously hypertensive SHR rats. The abscissa axis shows the time after drug administration in hours, the ordinate axis shows the values ​​of mean BP in percent. Shown are the average values ​​for 6-12 animals for each group as a percentage of the initial values ​​(131-142 mmHg). Group designations: • - control, n = 12; D - 0.03 mg / kg, n = 6; □ - 0.1 mg / kg, n = 6; ▲ - 0.3 mg / kg, n = 12; o - 1.0 mg / kg, n = 6; ■ - 3.0 mg / kg, n = 6. The presented data show that riociguat, when administered orally once at doses ranging from 0.03 to 3.0 mg / kg, causes a prolonged and dose-dependent decrease in mean BP in SHR rats.

[0032] Fig. 2, taken from publication [8], shows the effect of riociguat (BAY 63-2521) administered orally at doses of 1 and 10 mg / kg on pulmonary arterial pressure and systemic arterial pressure in rabbits with a model of pulmonary arterial hypertension. The abscissa axis shows the test compounds: BAY 63-2521, sildenafil and their combination; the ordinate axis shows the values ​​of systemic BP as a percentage of the initial level. Column designations in the figure: > - pulmonary arterial pressure; ■ - systemic arterial pressure; the * sign indicates statistically significant differences from the control (p < 0.05). The presented data show that riociguat (BAY 63-2521) at doses of 1 and 10 mg / kg reduces both pulmonary arterial pressure and systemic arterial pressure to an equal extent in a rabbit model of pulmonary arterial hypertension.

[0033] Fig. 3, taken from publication

[0011] , shows the effect of praliciguat (IW-1973) administered orally for 3 days at doses from 0.3 to 10 mg / kg on systemic arterial pressure in normotensive Wistar rats and spontaneously hypertensive SHR rats. The abscissa axis shows the doses of IW-1973 in mg / kg (0 - vehicle, 0.3, 1, 3 and 10 mg / kg); the ordinate axis shows the values ​​of decrease in mean arterial pressure on the 3rd day relative to the initial level in mmHg. The number of animals in each group was 6. The signs *, ** and *** mean statistically significant differences from the control: * - p < 0.05, ** - p < 0.01; *** - p < 0.001. The presented data show that praliciguat (IW-1973) at doses from 0.3 to 10 mg / kg reduces mean BP in both spontaneously hypertensive SHR rats and normotensive Wistar rats, which reflects the side hypotensive effect of praliciguat.

[0034] Fig. 4 shows the results of a study of the effect of a compound of formula I upon its single oral administration at doses of 5, 10 and 20 mg / kg on systemic arterial pressure in normotensive CD rats and spontaneously hypertensive SHR rats. The abscissa axis shows the time after administration of the drug in hours, and the ordinate axis shows the values ​​of mean BP in mm Hg. The data presented show that GRS causes a long-term and dose-dependent decrease in mean BP in spontaneously hypertensive rats, but does not have any effect on systemic BP in normotensive rats.

[0035] Fig. 5 schematically shows the approach to assessing the parameters of the vasodilatory function of the vascular endothelium based on the area of ​​the triangle above the mean arterial pressure recovery curve, where one leg represents the magnitude of the decrease in mean arterial pressure (AmAP) in response to the introduction of a vasodilator, and the other leg represents the time of mean arterial pressure recovery.

[0036] The claimed technical result and the new identified properties of the compound of formula I are confirmed by the following specific examples of its use.

[0037] Example 1. Effect of the compound of formula I on arterial pressure in normotensive and spontaneously hypertensive rats

[0038] The study was conducted using male normotensive CD Sprague Dawley rats weighing 330-400 g and spontaneously hypertensive SHR rats weighing 240-275 g. The animals were administered the compound of formula I (code name of the compound - GRS) intragastrically at doses of 5, 10 and 20 mg / kg. A 0.5% solution of carboxymethylcellulose was used as a carrier for intragastric administration. Animals of the control groups received only a 0.5% solution of carboxymethylcellulose. Systemic arterial pressure indicators - systolic BP (SBP) and diastolic BP (DBP) were measured before administration and 1, 2, 4, 8 and 24 hours after a single administration of the substances. Then GRS was administered once a day for 14 days, then systolic and diastolic BP were measured after 1 hour, 1, 3 and 7 days after the 14-day administration. Mean arterial pressure (MAP) was calculated using the formula: MAP = DAP + (SAP - DAP) / 3.

[0039] GRS exerted a pronounced dose-dependent antihypertensive effect in spontaneously hypertensive SHR rats. The most pronounced effect in terms of amplitude and duration was observed with intragastric administration of GRS at doses of 10 and 20 mg / kg - MAP in SHR rats decreased by 45% after 1 hour, reaching the level of normotensive CD rats, the effect lasted for at least 24 hours. During 14 days of administration, the antihypertensive effect of GRS remained unchanged. Three days after the end of the substance administration, BP of SHR rats returned to the initial level. At the same time, GRS did not affect the BP level of animals with normal pressure, which follows from the data shown in Fig. 4 and in Tables 1, 2.

[0040] Thus, the compound of formula I, unlike riociguat and other known sGC stimulants and activators, does not have any effect on systemic blood pressure at its normal level, but at the same time has a pronounced antihypertensive effect in animals with elevated blood pressure (SHR rats).

[0041] Table 1 - Results of measurements of mean BP after a single intragastric administration of the compound of formula I (GRS) (X ± SE)

[0042] Notes'.

[0043] 1. Number of animals in each group n = 6; 2. The sign “*:” indicates statistically significant differences with the indicator in the “SHR Control” group.

[0044] (p < 0.05).

[0045] Table 2 - Results of the measurement of mean BP after repeated (14-day) intragastric administration of the compound of formula I (GRS) (X ± SE) Notes'.

[0046] 1. The number of animals in each group n = 6;

[0047] 2. The sign “*” indicates statistically significant differences with the indicator in the “SHR Control” group (p < 0.05).

[0048] Example 2. Effect of compound of formula I on blood pressure in a healthy person

[0049] The effect of the compound of formula I (GRS) on systemic BP in humans was assessed in phase I clinical trials conducted in accordance with the permission of the Russian Ministry of Health under Protocols No. GRS-2018-02 Version 1.1 dated 06 / 25 / 2018 and No. GRS-2020-08 Version 1.0 dated 08 / 01 / 2020, with single and multiple administration of the GRS drug by healthy male volunteers.

[0050] Some volunteers (30 people) took the study drug GRS in different doses (20, 40, 80, 120, 160 and 200 mg) or placebo (0 mg) once. There were 4 people in each dose group, and 6 people in the placebo group. Blood pressure indicators (systolic and diastolic BP) were assessed before taking the drug (0 h) and after taking the drug - after 1, 2, 6, 12 and 24.

[0051] Another group of volunteers (48 people) took the study drug GRS in doses of 20, 40 and 60 mg / day daily for 7 days. There were 12 people in each dose group, and 12 people in the placebo group. Systemic arterial pressure indicators - systolic BP (SBP) and diastolic BP (DBP) were assessed before the start of drug administration (0 h) and after drug administration - after 0.75, 1.25, 1.5, 2, 3, 12 and 24 h.

[0052] The results presented in Tables 3 and 4 show that the compound of formula I, when administered once (at doses of 20 to 200 mg) and multiple times (at doses of 20, 40 and 60 mg / day daily for 7 days), does not affect blood pressure in a healthy person with initially normal blood pressure --- at no time point or in any dose group are there any significant differences in systolic or diastolic blood pressure from baseline values ​​(before taking the drug) or from values ​​in the placebo group.

[0053] Thus, the compound of formula I, unlike riociguat and other known sGC stimulants and activators, does not have a negative side hypotensive effect on systemic blood pressure at its normal level in a healthy person.

[0054] Table 3 - Results of blood pressure measurements after a single dose of compound of formula I (GRS) in volunteers (X ± SE)

[0055] Table 4 - Results of blood pressure measurements on days 1 and 7 after repeated administration of the compound of formula I (GRS) by volunteers (X ± SE)

[0056] Example 3. Effect of the compound of formula 1 on arterial pressure and other hemodynamic parameters in a model of chronic thromboembolic pulmonary hypertension in minipigs

[0057] The study was conducted on mini-pigs, males aged 34.4 ± 7.4 months and weighing 81.5 ± 7.0 kg. Modeling of chronic thromboembolic pulmonary hypertension (CTEPH) was performed by an original method based on the publications of Mercier O. et al.

[0014] , Aguero J. et al.

[0015] and Loisel F. et al.

[0016] by embolization of arteries feeding the lower lobes of the left and right lungs with a non-adhesive adhesive composition. Intra-arterial administration of a composition of this type leads to effective filling of large and small arterioles and arteries with spherical emboli, which are capable of sticking together and are not absorbed during the entire study period. To form CTEPH, selective embolization of the lower lobe branches of the right and left pulmonary arteries was performed in 15 animals. Embolization was performed by introducing a non-adhesive polymer adhesive composition into the target arteries. The volume of the injected composition in each case varied individually within 5-10 ml.Cessation of blood flow in the embolized arteries was monitored by contrast angiography.

[0058] The development of CTEPH occurred on average within 42 days after embolization, which was recorded using ultrasound and cardiac catheterization. The main sign of developing CTEPH was an increase in pressure in the pulmonary artery of more than 25 mm Hg. Histological studies in the tissues and vessels of the lungs revealed morphological changes characteristic of developing CTEPH of the precapillary type with the formation of extensive zones of atelectasis (collapse of lung tissue), obliteration of the lumen of small and medium-diameter blood vessels with the formation of intravascular thrombi, hypertrophy of the walls of small blood vessels with collagenization of the wall and the loss of its typical structure.

[0059] After confirmation of CTEPH formation, the animals were randomized into 3 groups. The first group received treatment with the compound of formula I (40 mg divided into 20 mg twice daily, orally), the second received riociguat (4 mg divided into 2 mg twice daily, orally), and the third (control) group of animals was observed without therapy (received the carrier - starch). The duration of the therapy course was 36 days.

[0060] After 36 days, the animals underwent diagnostic cardiac probing to assess the effectiveness of the therapy. For this purpose, a Corodyn catheter (B. Braun, Germany) was inserted into the right ventricle and then into the pulmonary artery through an introducer into the anesthetized animals under fluoroscopy control using a mobile X-ray unit OEC9900 (GE Healthcare, USA), with the help of which the hemodynamic parameters of the pulmonary circulation were measured: average pressure in the pulmonary artery, pulmonary artery wedge pressure and cardiac output.

[0061] A course of administration of the compound of formula I, as well as riociguat, resulted in a pronounced therapeutic effect: a decrease in the average pulmonary artery pressure by 44-45% (from 27.8 to 15.6 and 15.3 mmHg, respectively) and pulmonary vascular resistance by 2.4 times (from 397.7 mmHg to 165.8 and 168.8 mmHg, respectively). The pulmonary artery wedge pressure did not change significantly. Another significant criterion for the effectiveness of CTEPH therapy is a change in cardiac output. This parameter characterizes the pumping function of the right ventricle of the heart. During the modeling of the pathology, a decrease in cardiac output and its restoration after treatment with both drugs were observed (Table 5).

[0062] Table 5 - Dynamics of hemodynamic parameters of the pulmonary circulation in minipigs with a CTEPH model after a 36-day course of administration of the compound of formula I (GRS) and riociguat (X ± SE)

[0063] Notes: 1. The sign “*” indicates statistically significant differences with the preoperative indicator (p < 0.05),

[0064] 2. The sign " # " means statistically significant differences with the indicator in the control group (P < 0.05).

[0065] Thus, a course of treatment with the compound of formula I (GRS) has a pronounced therapeutic effect in CTEPH, normalizing the main parameters of hemodynamics of the pulmonary circulation, which are impaired in CTEPH - it reduces the increased mean pressure in the pulmonary artery and pulmonary vascular resistance, and also restores the reduced cardiac output of the right ventricle.

[0066] Example 4. Effect of compound of formula 1 on hemodynamic parameters and endothelial dysfunction in a model of pulmonary arterial hypertension in rats

[0067] The study was performed using male Wistar rats weighing 250–320 g. The modeling of PAH was reproduced by a single subcutaneous injection of monocrotaline at a dose of 60 mg / kg. Monocrotaline (Sigma-Aldrich, USA) was dissolved in 0.5 N HCl, then the pH was adjusted to 7.4 using 0.5 N NaOH

[0017] .

[0068] To study the effect of GRS on blood pressure in the right ventricle of the heart and right ventricular hypertrophy, some rats were divided into 4 groups: intact animals (n = 6), control animals with PAH without treatment (n = 8), animals with PAH that were administered a compound of formula I (GRS administration, n = 8), and animals with PAH that were administered the comparison drug riociguat (n = 8).

[0069] To study the effect of GRS on endothelial dysfunction, another part of the rats was also divided into 4 groups: intact animals (p :=:6), control animals with PAH without treatment (n = 8), animals with PAH that were administered the compound of formula I (GRS administration, n = 8) and animals with PAH that were administered the reference drug riociguat (n = 8).

[0070] GRS (10 mg / kg) and riociguat (1 mg / kg) as a suspension in 1% starch mucus were administered intragastrically daily for 2 weeks, starting from the 15th day after monocrotaline administration. Intact animals and control group rats received 1% starch mucus according to the same scheme. The GRS dose used in the study (10 mg / kg) corresponds to the average effective dose at which its antihypertensive effect is manifested. The riociguat dose used in the study (1 mg / kg) is close to the upper limit of the dose range (0.03-3 mg / kg) at which its antihypertensive effect is manifested, i.e. it even exceeds the average effective dose.

[0071] Surgical intervention to assess hemodynamic parameters in the right ventricle of the heart was performed under isoflurane anesthesia. Isoflurane inhalation was performed using an Ugo Basile 21050 isoflurane anesthesia apparatus. Right ventricular pressure was measured using an MP150 high-speed data acquisition and analysis system (BiopacSystems, Inc., USA) and a pressure measurement unit (OpSens, Canada) with a TSD282 microsensor. Rats under isoflurane anesthesia had a pressure microsensor inserted into the right ventricle of the heart through the jugular vein. Data were recorded and processed on a computer using the AcqKnowledge 4.2 for MP 150 program. The pressure curve was used to determine the maximum (Pmax, mmHg) and minimum (Pmm, mmHg) pressure in the right ventricle, the maximum rate of pressure change during a contraction cycle (dP / dtmax, mmHg / s), and the contractile index (CI, 1 / s).

[0072] After recording the pressure in the right ventricle of the heart, the rats were euthanized routinely using CO2 inhalation. The heart was then removed and the heart and right ventricular wall weights were determined. Right ventricular hypertrophy was assessed using the following parameters: right ventricular wall weight / body weight (RVW / BW, mg / g) and right ventricular wall weight / heart weight (RVW / HW, mg / mg).

[0073] To assess the vasodilatory activity of the vascular endothelium, a catheter was implanted into the left carotid artery of rats under inhalation anesthesia (isoflurane). Systemic arterial pressure was recorded using an MP150 high-speed data acquisition and analysis system (BiopacSystems, Inc., USA) with a DA100C general-purpose amplification module and a TSD104A pressure sensor. Data were recorded and processed on a computer using the AcqKnowledge 4.2 for MP 150 program. Changes in mean arterial pressure (MAP) were recorded in response to functional vascular tests: endothelium-dependent vasodilation after intravenous administration of acetylcholine (ACh) at a dose of 5 μg / kg and endothelium-independent vasodilation after intravenous administration of sodium nitroprusside (NP) at a dose of 10 μg / kg. The administration of ACh and NP was carried out into the right femoral vein in a volume of 100 μl.To assess the degree of vascular dilation during the tests, the area of ​​the triangle above the mean arterial pressure recovery curve was used, where one leg represented the magnitude of the mean arterial pressure decrease (MAP) in response to the introduction of the vasodilator (mm Hg), and the other ~ the time of mean arterial pressure recovery after the test (Fig. 5). The degree of endothelial dysfunction in experimental animals was assessed by the endothelial dysfunction coefficient (EDC), which is the ratio of the area of ​​the triangle above the mean arterial pressure recovery curve after the introduction of NP to the area of ​​the triangle above the mean arterial pressure recovery curve after the introduction of ACh [18, 19].

[0074] The results of the evaluation of the effect of the compound of formula I on the hemodynamic parameters in the right ventricle of the heart are presented in Table 6. Table 6 - Effect of the compound of formula I (GRS) on blood pressure parameters in the right ventricle of the heart in rats with PAH

[0075] Notes'.

[0076] 1. The sign “*” indicates significant differences compared to values ​​in intact animals (P < 0.05).

[0077] 2. The sign " # " means reliable differences compared to the values ​​in animals of the control group (p < 0.05)

[0078] Four weeks after monocrotaline administration, the control group rats showed a pronounced (2.25-fold) increase in pressure (Pmax) in the right ventricle of the heart, which is typical for PAH, compared to intact animals. Accordingly, the maximum rate of pressure change per contraction cycle (dP / dtmax) increased by 1.8 times. The increase in pressure in the right ventricle in PAH reflects an increase in pressure in the pulmonary circulation (pressure in the pulmonary artery) due to an increase in pulmonary vascular resistance against the background of progressive damage to the vessels and tissues of the lung.

[0079] In rats with PAH treated with GRS and riociguat, the value of Ppix in the right ventricle of the heart was statistically significantly lower compared to the control, although it did not decrease to the level in intact animals. No statistically significant differences in the parameters Pmax, Pmin, CI and dP / dtmax were found between the groups of animals treated with GRS and riociguat.

[0080] Thus, the compound of formula I (GRS) and riociguat have a comparable therapeutic effect in animals with a PAH model - they reduce the pressure in the right ventricle of the heart, which is elevated in PAH.

[0081] The results of the evaluation of the effect of the compound of formula I on the parameters characterizing endothelial dysfunction are presented in Table 7. Table 7 - Effect of GRS on endothelial dysfunction in rats with pulmonary arterial hypertension

[0082] Notes'.

[0083] 1. The sign “*” indicates significant differences compared to values ​​in intact animals (p < 0.05).

[0084] 2. The sign " # " means reliable differences compared to the values ​​in rats of the control group (p < 0.05).

[0085] 3. The sign < > indicates significant differences compared to the values ​​in rats treated with riociguat (p < 0.05).

[0086] Four weeks after monocrotaline administration, the MAP value, as well as the values ​​of the MAP decrease (AMAP) in response to both ACh and NP, were statistically significantly lower in the control group rats than in the intact group, which reflects the formation of endothelial dysfunction in animals with PAH. As a result, the EDC value increased to 2.36 ± 0.27 compared to 1.80 ± 0.06 in the control, although this decrease did not reach the level of statistical significance.

[0087] It is important to note that the animals of the control group had systemic hypotension - the initial mean arterial pressure, recorded before the administration of ACh or NP, was significantly lower than in the animals of the intact group.

[0088] The course administration of riociguat caused opposite changes in A MAP and recovery time of MAP in response to the administration of ACh and NP, which ultimately did not lead to a statistically significant change in EDC compared to the control group. It is important to note that rats receiving riociguat developed even more pronounced hypotension - the value of MAP before the administration of ACh and NP was 87 ± 3 and 88 ± 4, respectively, while in the control - 92 ± 3 and 97 ± 2, and in intact animals - 111 ± 4 and 114 ± 4. This reflects the above-described side hypotensive effect of riociguat on systemic BP.

[0089] With a course of GRS administration to animals with a PAH model, the value of MAP did not statistically significantly differ from the values ​​in the group of intact animals, which indicates that GRS does not have a side hypotensive effect on systemic BP, unlike riociguat. Moreover, the administration of GRS leads to the normalization of systemic BP, which is reduced in animals with PAH - the value of the initial MAP in animals receiving GRS did not statistically significantly differ from the values ​​of the initial MAP in intact animals (Table 7).

[0090] In animals receiving GRS, upon administration of ACh (endothelium-dependent vasodilation), the ASmAP value was statistically significantly higher than in the control and did not differ from the value in the intact group, and the recovery time of MAP was statistically significantly higher compared to the value in the intact group and did not differ from the value in the control and the group with riociguat. Upon administration of NP (endothelium-independent vasodilation) to rats receiving GRS, the ASmAP value was statistically significantly higher compared to the value in the animals of the group receiving riociguat and did not differ from the value in intact animals, and the recovery time of MAP was statistically significantly lower than in the group with riociguat and also did not differ from the values ​​in the control and in intact animals.The observed changes in ASmAP and the recovery time of MAP in response to endothelium-dependent and independent stimuli led to the fact that the value of EDP after a course of GRS administration statistically significantly decreased to 1.59 ± 0.13 compared to 2.36 ± 0.27 in control animals, which indicates the normalization of the vasodilating function of the endothelium (Table 7).

[0091] Thus, the course administration of the compound of formula I (GRS) in animals with the PAH model led to the following effects:

[0092] 1) normalization of hemodynamics in the pulmonary circulation - reduction of elevated pressure in the right ventricle of the heart in PAH comparable to the effect of riociguat;

[0093] 2) normalization of systemic arterial pressure, which is reduced in PAH, in contrast to riociguat, which, on the contrary, had a hypotensive effect;

[0094] 3) elimination of signs of endothelial dysfunction - normalization of the vasodilating function of the endothelium, reduced in PAH.

[0095] Sources of Information

[0096] 1. Humbert М, Guignabert С, Bonnet S, Dorfmuller Р, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan 24;53(1): 1801887. doi: 10.1183 / 13993003.01887-2018.2 2. Huertas A, Guignabert C, Barbera JA, et al. Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: highlights from basic research to therapy. Eur Respir J. 2018 Apr 4;51(4): 1700745. doi: 10.1183 / 13993003.00745-2017.

[0097] 3. Roberto B. Evora, P., M. Evora, P., C. Celotto, A., J. Rodrigues, A., & E. Joviliano,E.

[0098] (2012). Cardiovascular Therapeutics Targets on the NO sGC cGMP Signaling Pathway: A Critical Overview. Current Drag Targets, 13(9), 1207-1214. doi: 10.2174 / 138945012802002348.

[0099] 4. Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011 May 24;123(20):2263-73. doi: 10.1161 / CIRCULATION AH A.110.981738.

[0100] 5. Klinger J.R., Kadowitz P.J. The nitric oxide pathway in pulmonary vascular disease. Am J Cardiol. 2017 Oct 15;120(8S):S71-S79. doi: 10.1016 / j.amjcard.2017.06.012.

[0101] 6. Schmidt H.H., Schmidt P.M., Stasch J.P. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009;(191):309-39. doi: 10.1007 / 978-3-540- 68964-5 14.

[0102] 7. Mittendorf, J., Weigand, S., Alonso-Alija, C., Bischoff, E., Feurer, A., Gerisch, Mi, Stasch, J.-P. (2009) Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4(5):853— 865. doi: 10.1002 / cmdc.200900014.

[0103] 8. Schermuly R. T., Stasch J-P., Pullamsetti S. S., Middendorff R., Muller D. et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. European Respiratory Journal 2008 32: 881-891; DOI: 10.1183 / 09031936.00114407.

[0104] 9. Khaybullina D., Patel A., Zerilli T. Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. P&T. 2014 Nov;39(l l):749-58. PMCID: PMC4218670.

[0105] 10. Armstrong P.W., Pieske B., Anstrom K.J. et al. Vericiguat in Patients with Heart Failure and

[0106] Reduced Ejection Fraction. N Engl J Med 2020; 382: 1883-1893

[0107] DOI: 10.1056 / NEJMoal915928.

[0108] 11. Tobin JV, Zimmer DP, Shea C. et al. Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease. J Pharmacol Exp Ther 365:664-675, June 2018 https: / / doi.org / 10.1124 / ipet.117.247429.

[0109] 12. Gheorghiade M., Greene SJ Filippatos G. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase lib COMPOSE program in acute heart failure syndromes. European Journal of Heart Failure (2012) 14, 1056-1066 doi: 10.1093 / eurjhf / hfs093.

[0110] 13. Patent RU 2483066 dated 27.05.2013 “New antithrombotic and antiatherosclerotic agent and method for its production (variants)”.

[0111] 14. Mercier О, Tivane A, Dorfmuller Р, de Perrot М, Raoux F, Decante В, et al. Piglet model of chronic pulmonary hypertension. Pulm Circ. (2013) 3:908-15. doi: 10.1086 / 674757

[0112] 15. Aguero J, Ishikawa K, Fish KM, Hammoudi N, Hadri L, Garcia-Alvarez A, et al. Combination proximal pulmonary artery coiling and distal embolization induces chronic elevations in pulmonary artery pressure in Swine. PLoS ONE. (2015) 10:e0124526. doi: 10.1371 / journal. pone.0124526

[0113] 16. Loisel F, Provost B, Guihaire J, Boulate D, Arouche N, Amsallem M, et al. Autologous endothelial progenitor cell therapy improves right ventricular function in a model of chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. (2019) 157:655-66. e7. doi: 10.1016 / j.jtcvs.2018.08.083.

[0114] 17. Schermuly, RT / RT Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, H. Yilmaz, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004 Jan 1; 169(1): 39-45. doi: 10. 1164 / rccm.200302-2820C.

[0115] 18. Laursen JB, Boesgaard S, Poulsen HE, Aldershvile J. Nitrate tolerance impairs nitric oxide-mediated vasodilation in vivo. Cardiovascular Res. 1996 May;31(5):814-819. doi: 10.1016 / 0008-6363(96)00027-2.

[0116] 19. Pokrovsky, M. V. Methodological approaches for quantitative assessment of endothelial dysfunction development in LNAME-induced nitric oxide deficiency model in an experiment / M. V. Pokrovsky, V. I. Kochkarov, T. G. Pokrovskaya - Text: direct / 7 Rus. journal of immunology. - 2006. - Vol. 96. - P. 60-61.

Claims

Invention formula 1 . Use of 2-[2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]-2-cyanoethylidene]indolin-3-one of formula I as a treatment for pulmonary hypertension without the side effect of hypotensive action on systemic arterial pressure.

2. Use of the agent according to I. 1 to normalize the hemodynamic parameters of the pulmonary circulation, including a decrease in elevated pressure in the pulmonary artery and right ventricle of the heart, a decrease in pulmonary vascular resistance and restoration of cardiac output of the right ventricle.

3. Use of the agent according to paragraph 1 for pulmonary arterial hypertension 4. Use of the agent according to paragraph 1 for chronic thromboembolic pulmonary hypertension.

5. Use of the agent according to paragraph 1, characterized in that it is used for administration to mammals in doses from 1.5 to 200 mg.

Citation Information

Patent Citations

  • Carboxamide derivatives

    EA030938B1

  • Derivatives of sitaxenthan

    RU2622386C2

  • Combination therapy for treatment of pulmonary hypertension

    RU2763525C2

  • Compositions and methods for the treatment of pulmonary arterial hypertension

    WO2017192553A1